

5th December 2014

The ASX Market Announcements Platform
ASX Limited
By E-lodgement

ASX Announcement**COMPLETION OF CAPITAL CONSOLIDATION**

Prescient Therapeutics Limited (Prescient or the Company)(formerly Virax Holdings Limited) advises that its one (1) for twenty (20) capital consolidation was completed today.

The consolidation was achieved through the conversation of twenty (20) fully paid ordinary shares and unlisted options into one (1) fully paid ordinary share or unlisted option, was approved by an ordinary resolution of shareholders passed at the Company's Annual General Meeting held on 28 November 2014.

The table below summarises the Prescient's capital structure pre and post consolidation.

SECURITIES	PRE-CONSOLIDATION		POST-CONSOLIDATION	
	Number	Exercise Price	Number	Exercise Price
Ordinary Shares	920,947,371		46,048,216	
Unlisted options expiring 12/10/2017	87,700,000	\$0.005	4,385,000	\$0.10

The Company confirms that where the capital consolidation resulted in an entitlement to a fraction of a share or option, that fraction was rounded up to the nearest whole number of shares or options. The confirmation statement advising holders of their revised holdings will be mailed shortly.

Yours faithfully

Sean Henbury
Company Secretary

Ends.

For further information contact:

Mr. Rudi Michelson
Monsoon Communications
Ph: +61 (0) 3 9620 3333

Dr Rob Crombie
Managing Director
Prescient Therapeutics Limited
Ph: +61 (0) 3 9982 4563



About Prescient Therapeutics

Prescient Therapeutics Limited is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. GGTI-2418 is expected to enter Phase 1b/2 clinical trials in breast cancer and multiple myeloma in early 2015.

Prescient Therapeutics has also obtained shareholder approval to acquire oncology company AKTivate Therapeutics and its novel TCN-P cancer drug. The Company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defence and National Cancer Institute.

In addition, the Company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.

